Rajshekhar Chakraborty, MD
Medical Oncology
Hematology/Oncology
Accepting New Patients
Virtual Visits/Telehealth
On the web
Overview
Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic.
During fellowship, he conducted outcomes research with a focus on quality of life and treatment-related toxicities in plasma cell disorders. After fellowship, he started his job as Assistant Professor of Medicine at the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center.
Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom’s macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.
Academic Appointments
- Assistant Professor of Medicine at CUMC
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Male
Schedule an Appointment
Virtual Visits/Telehealth
Virtual Visits allow you to connect with your provider from the comfort, convenience, and safety of your own home.
Phone Appointments
New and Existing Patients:
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Location(s)
Insurance Accepted
Aetna
- Aetna Signature Administrators
- EPO
- HMO
- Medicare Managed Care
- NY Signature
- POS
- PPO
- Student Health
Affinity Health Plan
- Essential Plan
- Medicaid Managed Care
Amida Care
- Special Needs
Cigna
- EPO
- Great West (National)
- HMO
- Medicare Managed Care
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross/Blue Shield
- EPO
- HMO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
- NYP Employee Plan
MagnaCare (National)
- MagnaCare
Medicare
- Railroad
- Traditional Medicare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
RiverSpring
- Special Needs
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- Empire Plan
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- Oxford Freedom
- Oxford HMO
- Oxford Liberty
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs
WellCare
- Medicaid Managed Care
- Medicare Managed Care
World Trade Center Health Plan
- World Trade Center Health Plan
*Before your appointment, please contact the doctor’s office or your insurance provider to verify that your insurance is accepted. This list of insurances can change, and the insurance plans listed may not be accepted at all office locations for this provider.
Research
Dr. Chakraborty’s research focus is on clinical trials of novel agents in multiple myeloma and AL amyloidosis. He will lead a multicenter investigator-initiated trial on venetoclax in relapsed/refractory t(11;14) light chain amyloidosis. He is also collaborating with the Department of Radiology to establish a whole body difussion- weighted MRI protocol for imaging-based reponse assessment in myeloma, and designing studies to incorporate it in assessment of minimal residual disease. He is an active member of the PROMOTION project led by the Health Outcomes Research Unit, GIMEMA, and has led a study looking at patient-reported outcome, reporting in randomized controlled trials of hematologic malignancies with their team.
Selected Publications
- Chakraborty R, Cannella L, Cottone F, Efficace F. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematology. 2020 Dec;7(12):e892-e901. PMID: 33242446
- Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Annals of Hematology. 2020 May 7 [Epub ahead of print]. PMID: 32382772
- Chakraborty R, Rybicki L, Nakashima MO, Dean RM, Faiman BM, Samaras CJ, Rosko N, Dysert H, Valent J, Anwer F. Characterization and prognostic impact of immunoparesis in relapsed multiple myeloma. British Journal of Haematology. 2020 Feb 28 [Epub ahead of print]. PMID: 32018328
- Chakraborty R, Majhail N. Treatment and Disease-related Complications in Multiple Myeloma: Implications for Survivorship. American Journal of Hematology. 2020 Feb 22 [Epub ahead of print]. PMID: 32086970
- Basali D, Chakraborty R, Rybicki L, Rosko N, Reed J, Karam M, Schlueter K, Dysert H, Kalaycio M, Valent J. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. British Journal of Haematology. 2020 Feb 3 [Epub ahead of print]. PMID: 32012228
- Chakraborty R, Bin Riaz I, Malik SU, Marneni S, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. Cancer. 2020 Jan 8 [Epub ahead of print]. PMID: 31913498
- Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, Faiman BM, Kalaycio M, Samaras BJ, Majhail NS, Valent J. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology. 2019 Apr;94(4):439-445. PMID: 30663805
- Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018 Mar;32(3):712-718. PMID: 28848227
- Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017 Aug;102(8):1439-1445. PMID: 28473618
- Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of post-transplant response and minimal residual disease on survival in myeloma with high-risk cytogenetics. Biology of Blood and Marrow Transplantation. 2017 Apr;23(4):598-605. PMID: 28115277
- Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer Journal. 2016 Dec 16;6(12):e512. PMID: 27983726
For a complete list of publications, please visit PubMed.gov